National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 4 of 11
Prospective International Study of Coronary Subtraction Using 320 Detector Row CT (CorSub)
NCT02303067
Genes Involved in Lipid Disorders
NCT02311335
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
NCT02298933
Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0
NCT02290392
Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access
NCT02280824
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
NCT02055222
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
NCT02231853
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
NCT02226861
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
NCT02225132
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
NCT02208037
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)
NCT02055209
Effect of Fasting on the NLRP3 Inflammasome
NCT02122575
Links Between Inflammation and Cardiometabolic Diseases
NCT01934660
Extended Dosing With Eltrombopag for Severe Aplastic Anemia
NCT01891994
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
NCT01866839
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals
NCT01862029
Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance
NCT01862757
Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support
NCT01932294
Longitudinal Observational Study of Severe Asthma
NCT01780142
Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)
NCT04737720
The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)
NCT01778569
Myocardial Perfusion and Scarring in Congenital Heart Disease
NCT01639937
Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol
NCT01783990
Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)
NCT01585402
Genetics and Pain Severity in Sickle Cell Disease
NCT01441141
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
NCT01629082
Microvessels and Heart Problems in Sickle Cell Disease
NCT01602809
Blood Flow and Pain Crises in People With Sickle Cell Disease
NCT01568710
Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
NCT01273207
Hemoglobin and Iron Recovery Study
NCT01555060
Stem Cell Injection to Treat Heart Damage During Open Heart Surgery
NCT01557543
Mutations Associated With Parkinson s Disease
NCT01547832
Heart Imaging in Children With Muscular Dystrophy
NCT01633242
Carbon Monoxide Levels and Sickle Cell Disease Severity
NCT01547793
Improving Blood Stem Cell Collection and Transplant Procedures
NCT01517035
Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications
NCT01633229
Pericardiocentesis With Magnetic Resonance Imaging
NCT01479569
Ultra Low Dose Interleukin-2 in Healthy Volunteers
NCT01445561
Ultrasound and Other Images of Artery Blockages
NCT01419574
Danazol for Genetic Bone Marrow and Lung Disorders
NCT01441037
Decitabine for High-Risk Sickle Cell Disease
NCT01375608
Cross-sectional Characterization of Idiopathic Bronchiectasis
NCT01264055
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
NCT00961064
Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders
NCT01316796
Real-time MRI Right Heart Catheterization Using Passive Catheters
NCT01287026
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
NCT01287078
Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers
NCT01281995
Systolic Blood Pressure Intervention Trial
NCT01206062
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
NCT01212900
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
NCT01193283
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets.Report a data error.